The drug development pipeline is key to bringing new therapies to people with Parkinson’s disease (PD). With major breakthroughs in research in the past year, including a new biomarker for PD, The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative (PPMI) study and other initiatives can be leveraged to create better designed trials. This audio from our Third Thursdays Webinar features a conversation about all the ways clinical trial design is changing, and why leaders in the space believe those changes will lead to better treatments. The webinar includes contributions from a person with PD, a researcher and an industry leader.
If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet. If you enjoyed what you heard, share it with a friend or leave a review on iTunes. It helps listeners like you find and support our mission.
This conversation is led by Maggie Kuhl, vice president of patient engagement at The Michael J. Fox Foundation (MJFF), and features our panelists:
-
Tanya Simuni, MD, FAAN, professor of neurology and division head of the Parkinson’s Disease and Movement Disorders Center at Northwestern University. She is also the leader of a PPMI site and part of the initiative’s executive steering committee.
-
Rick Grant is a PPMI participant who was diagnosed with Parkinson’s in 2018.
-
Niraj Shanbhag, MD, PhD, is medical director at Takeda Pharmaceuticals, a global, research and development-driven pharmaceutical company.
View a transcript of this podcast.
Want to see the slides and other resources from the webinar? Watch on demand.
Join a study today to help speed progress toward better treatments and a cure for Parkinson’s disease. To search for studies in your area, visit Fox Trial Finder.
Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything.